Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease
- 17 August 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 15 (9) , 1105-1113
- https://doi.org/10.1517/13543784.15.9.1105
Abstract
(2006). Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. Expert Opinion on Investigational Drugs: Vol. 15, No. 9, pp. 1105-1113. doi: 10.1517/13543784.15.9.1105Keywords
This publication has 38 references indexed in Scilit:
- COPD: current therapeutic interventions and future approachesEuropean Respiratory Journal, 2005
- Initiation of maintenance treatment of persistent asthma: salmeterol/fluticasone propionate combination treatment is more effective than inhaled steroid aloneRespiratory Medicine, 2004
- Pathophysiology of airflow limitation in chronic obstructive pulmonary diseaseThe Lancet, 2004
- The global burden of asthma: executive summary of the GINA Dissemination Committee ReportAllergy, 2004
- Sildenafil in erectile dysfunction: a critical reviewCurrent Medical Research and Opinion, 2003
- Oxidative Stress and Gene Transcription in Asthma and Chronic Obstructive Pulmonary Disease: Antioxidant Therapeutic TargetsCurrent Drug Targets - Inflammation & Allergy, 2002
- Asthma in the United States: burden and current theories.Environmental Health Perspectives, 2002
- Cyclic nucleotide phosphodiesterasesJournal of Allergy and Clinical Immunology, 2001
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Effect of Oral Milrinone on Mortality in Severe Chronic Heart FailureNew England Journal of Medicine, 1991